Compare EIG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | EVO |
|---|---|---|
| Founded | 2000 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 754.0M | 934.1M |
| IPO Year | 2006 | N/A |
| Metric | EIG | EVO |
|---|---|---|
| Price | $44.06 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 167.4K | 85.0K |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $858,700,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $1.26 | $10.05 |
| P/E Ratio | $84.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.73 | $2.31 |
| 52 Week High | $49.39 | $4.48 |
| Indicator | EIG | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 53.04 |
| Support Level | $41.01 | $2.88 |
| Resistance Level | $44.38 | $3.36 |
| Average True Range (ATR) | 0.92 | 0.09 |
| MACD | 0.22 | -0.01 |
| Stochastic Oscillator | 89.61 | 54.34 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.